Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 196

Similar articles for PubMed (Select 19698807)

1.

The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.

Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J.

Vaccine. 2009 Oct 19;27(44):6196-202. doi: 10.1016/j.vaccine.2009.08.004. Epub 2009 Aug 19. Erratum in: Vaccine. 2010 Aug 9;28(35):5755.

PMID:
19698807
2.
3.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

4.

US cervical cancer prevention efforts are falling short.

McCarthy M.

BMJ. 2014 Nov 7;349:g6716. doi: 10.1136/bmj.g6716. No abstract available.

PMID:
25381223
5.
6.

A systematic review of economic aspects of cervical cancer screening strategies worldwide: discrepancy between economic analysis and policymaking.

Nahvijou A, Hadji M, Marnani AB, Tourang F, Bayat N, Weiderpass E, Daroudi R, Sari AA, Zendehdel K.

Asian Pac J Cancer Prev. 2014;15(19):8229-37. Review.

7.

The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States.

Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.

Sex Transm Dis. 2014 Nov;41(11):656-9. doi: 10.1097/OLQ.0000000000000199.

PMID:
25299411
8.

HPV vaccinations--possibly necessary but not sufficient.

Ginsberg GM.

Lancet Glob Health. 2014 Jul;2(7):e367-8. doi: 10.1016/S2214-109X(14)70249-9. Epub 2014 Jun 9. No abstract available.

9.

Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.

Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T.

BMC Infect Dis. 2014 Jun 26;14:351. doi: 10.1186/1471-2334-14-351.

10.

[Cancer of cervix in Chile. Too much vaccine amid a neglected Papanicolau].

Fica A.

Rev Chilena Infectol. 2014 Apr;31(2):196-203. Spanish.

11.

Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.

Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N.

Vaccine. 2014 May 7;32(22):2645-56. doi: 10.1016/j.vaccine.2014.02.071. Epub 2014 Mar 22.

PMID:
24662710
12.

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

PLoS One. 2014 Mar 20;9(3):e89974. doi: 10.1371/journal.pone.0089974. eCollection 2014.

13.

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.

Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096.

PMID:
24331822
14.

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.

Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.

Vaccine. 2013 Dec 29;31 Suppl 5:F60-72. doi: 10.1016/j.vaccine.2012.07.093.

PMID:
24331749
15.

Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.

Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW.

PLoS One. 2013 Nov 18;8(11):e80639. doi: 10.1371/journal.pone.0080639. eCollection 2013.

16.

Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.

Ginsberg GM.

Vaccine. 2013 Nov 22;31 Suppl 8:I46-52. doi: 10.1016/j.vaccine.2012.04.110.

PMID:
24229719
17.

Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.

Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M.

Int J Cancer. 2014 May 1;134(9):2264-8. doi: 10.1002/ijc.28541. Epub 2013 Oct 31.

PMID:
24174175
18.

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Turner HC, Baussano I, Garnett GP.

PLoS One. 2013 Sep 26;8(9):e75552. doi: 10.1371/journal.pone.0075552. eCollection 2013.

19.

Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region.

Fonseca AJ, Ferreira LC, Neto GB.

Rev Assoc Med Bras. 2013 Sep-Oct;59(5):442-51. doi: 10.1016/j.ramb.2013.03.004. Epub 2013 Sep 14.

20.

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.

Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3.

PMID:
23830974
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk